BGPartner and Homburger advises on Noema financing round
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused investment firms Forbion and JEITO Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris, Gilde Healthcare and Invus Group to complete the round.
The proceeds of the Series B financing will be used to advance Noema Pharma’s clinical-stage assets. Following the closing of this Series B financing round, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the board of directors of Noema Pharma.
BGPartner advised co-lead investors Forbion and Jeito Capital on all Swiss legal matters and the negotiations of this Series B financing round. The core team consisted of partner Oliver Gnehm (pictured left) and Victoria Marty (associate) and furthermore comprised Olivier Bula (partner), Fabiola Weilenmann-Anthamatten (managing associate) and Geremia Stüssi (jurist).
Homburger advised Noema Pharma as transaction counsel in this Series B financing round. The team comprised partner Andreas Müller (pictured right), Margrit Marti, Timo Hasler, Thierry Burckhardt, Pepe Hünerwadel and Carolina Rodriguez (all corporate / m&a; healthcare / life sciences), Luca Dal Molin (IP / IT; healthcare / life sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (tax).